Krouzon Pharmaceuticals, Inc.
Krouzon Pharmaceuticals, Inc. is developing a first-in-class treatment for ultra-rare orphan pediatric skeletal disorders. Krouzon Pharmaceuticals, Inc. Team: Jacob V. P. Eswarakumar
Read MoreQlear Chemicals
Qlear Chemicals We develop novel permeabilization and optical clearing reagents for 3D imaging of intact, grossed anatomic pathology samples. Qlear Chemicals Team: Elif Alpoge
Read MoreCapCell Biologics
CapCell Biologics is treating rare diseases with implants composed of engineered cells in a protective mesh capsule. CapCell Biologics Team: Ben Young Jon Zaikowski
Read MoreEx Vivo Dynamics
Ex Vivo Dynamics is a medical device company developing BloodGuardTM platform technology to significantly reduce short and long term complication resulting from blood transfusion. Ex Vivo Dynamics Team: Daisy Lobo Xi Huang Alan Perlstein Mei-Mei Zhao
Read MorePHD Biosciences
We are developing an enzyme inhibitor with pico-‐molar binding affinity and minimal toxicity as a once daily, oral therapeutic for the treatment of triple-‐negative breast cancer. Nanomedics LLC Team: Michael Isaacman Andrew Mahon
Read MorePainQX
The PainQx System is algorithmic software that provides an accurate and objective way to measure chronic and acute pain in humans and animals. PainQX Team: Frank Minella
Read MoreNomoCan Pharmaceuticals
Utilizing a novel immunologic approach, NomoCan Pharmaceuticals is developing a targeted therapy for the treatment and prognosis of the most aggressive human cancer, pancreatic cancer. NomoCan Pharmaceuticals Team: Ehsan Sarafraz-Yazdi, PhD Kamyar Neshvadian, FRM
Read MoreZakan Theraputics
Zakan Therapeutics — A biological therapeutic that can directly attack metastatic cancer cells by delivering a payload of anti-cancer compounds while bypassing healthy cells. Zakan Theraputics Team: Arthee Jahangir Benjamin Caballero
Read MoreTaithera, Inc.
Aithera is a revolutionary nanomedicine bone targeted drug delivery controlled release platform technology for the treatment of musculoskeletal conditions focused initially on fracture healing & bone cancer (osteosarcoma is our first oncology target). Aithera Team: Seth Harlem, CEO Mo Chen, PhD, CSO
Read More